Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gail Panton"'
Autor:
Lindsey E. Roeker, Tatyana A. Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D. Zelenetz, Lorenzo Falchi, Jae H. Park, David J. Straus, Camila Pena Velasquez, Sonia Lebowitz, Yehudit Fox, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Teja Turpuseema, Michelle Purdom, Dana Paskalis, Hari P. Miskin, Peter Sportelli, Lori A. Leslie, Anthony R. Mato
Publikováno v:
Clinical Cancer Research. 28:3958-3964
Purpose: Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an “add on” approach for patients who had been treated with ibrutinib in the
Autor:
Anthony R. Mato, Lori A. Leslie, Peter Sportelli, Hari P. Miskin, Dana Paskalis, Michelle Purdom, Teja Turpuseema, Rosalba Martignetti, Sabrina Kdiry, Elizabeth McCarthy, Meghan C. Thompson, Carissa Laudati, Kristen Battiato, Yehudit Fox, Sonia Lebowitz, Camila Pena Velasquez, David J. Straus, Jae H. Park, Lorenzo Falchi, Andrew D. Zelenetz, Colleen Dorsey, Gail Panton, Victoria Falco, Jacob D. Soumerai, Tatyana A. Feldman, Lindsey E. Roeker
Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48c05b3ff2d51e9213b86e98036b3c6f
https://doi.org/10.1158/1078-0432.22487868
https://doi.org/10.1158/1078-0432.22487868
Autor:
Anthony R. Mato, Lori A. Leslie, Peter Sportelli, Hari P. Miskin, Dana Paskalis, Michelle Purdom, Teja Turpuseema, Rosalba Martignetti, Sabrina Kdiry, Elizabeth McCarthy, Meghan C. Thompson, Carissa Laudati, Kristen Battiato, Yehudit Fox, Sonia Lebowitz, Camila Pena Velasquez, David J. Straus, Jae H. Park, Lorenzo Falchi, Andrew D. Zelenetz, Colleen Dorsey, Gail Panton, Victoria Falco, Jacob D. Soumerai, Tatyana A. Feldman, Lindsey E. Roeker
Purpose:Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an “add on” approach for patients who had been treated with ibrutinib in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a26e24bc38e973d8f286db775058e90
https://doi.org/10.1158/1078-0432.c.6532596
https://doi.org/10.1158/1078-0432.c.6532596
Autor:
Kristen E. Battiato, Hari P. Miskin, Gail Panton, Camila Pena-Velasquez, Yehudit Fox, Victoria Falco, Rosalba Martignetti, Sabrina Kdiry, Lori A. Leslie, Elizabeth L. McCarthy, Lindsey E. Roeker, Carissa Laudati, Andrew D. Zelenetz, Jae H. Park, Sonia Lebowitz, Anthony R. Mato, Meghan C. Thompson, Lorenzo Falchi, Peter Sportelli, Jake D. Soumerai, David J. Straus
Publikováno v:
Blood. 138:395-395
Background: While time-limited novel agent combinations have demonstrated high overall response rates and durable responses for patients with chronic lymphocytic leukemia (CLL), they also have high rates of adverse events and possibly overtreat many